MEDICAL DEVICE SAFETY ALERT

Medtronic Evolut™ PRO+ 34mm Transcatheter Aortic Valve

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Bioprosthesis Model Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evolut™ PRO+</td>
<td>EVPROPLUS-34US</td>
</tr>
<tr>
<td></td>
<td>EVPROPLUS-34</td>
</tr>
</tbody>
</table>

November 30, 2022

Please share this information with physicians in your facility who use the Evolut™ TAV System.

Dear Physician:

This notification is to provide you with important information regarding the potential risk of valve infolding for the Medtronic Evolut™ PRO+ 34 mm Transcatheter Aortic Valve (TAV) models listed in the table above.  **Medtronic is not requesting any return of product from your facility.**

Infolding is a known phenomenon and occurs when the valve frame folds inward along a vertical line away from the valve inflow and appears as a seam in the frame or as overlapping frame cells on radiographic imaging (see figure 1). Infolding is different and distinct from valve under expansion and may be seen intraprocedurally at deployment or during recapturing of a valve.

Figure 1: Example of radiographic imaging depicting infolding.
Although the overall incidence of frame infolding is low in PRO+ TAVs, the PRO+ 34mm TAV has been associated with higher rates of infolding than other PRO+ sizes. From commercial launch (01 October 2019) to 31 August 2022, the PRO+ 34mm TAV infolding rate was 2.93%. Of this incidence rate, 0.32% resulted in serious adverse events, including two (2) deaths. Other serious adverse events may include unplanned surgery/intervention, such as surgical explant/valve replacement/aortic repair or implantation of a transcatheter valve within the initial valve (TAV in TAV), aortic regurgitation/insufficiency, paravalvular leak, hypotension, congestive heart failure, and aortic dissection.

In accordance with Medtronic’s commitment to patient safety, we will be updating the IFU (see Appendix A) with respect to:

- Detection of infold
- Removal of an infolded valve and replacement with a new system
- Pre-dilatation guidance

Patients who have been treated with an Evolut™ PRO+ TAV should continue to be managed according to your standard patient management protocols and do not require any additional management. The Evolut™ PRO+ System IFU will also be updated consistent with Appendix A.

Medtronic is notifying regulatory agencies regarding this communication and will obtain approvals for the updated IFU as required. Until the IFU update is available, physicians should continue to reference this communication.

**Physician Actions:**

Please complete the following actions:

- Review the updated instructions provided in Appendix A.
- Share this information with other physicians in your facility who use the Evolut™ TAV System.
- After review of this information, complete the enclosed Physician Confirmation Form and email to rs.cfqfca@medtronic.com.
- Additional training for you or your team can be made available upon request through your Medtronic Field Representative.

**Additional Information:**

---

1 Based on units sold worldwide.
Adverse reactions or quality problems experienced with this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

- Complete and submit the report online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)
- Regular Mail or Fax: Download form from [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm) or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Medtronic is committed to continuously enhancing the safety of our products and to provide you with relevant information that can improve patient care. If you have any questions regarding this communication, please contact your Medtronic Field Representative.

Sincerely,

Eliezer de Jesus Hernandez
Vice President, Quality
Structural Heart & Aortic

Enclosure: Appendix A - IFU updates
APPENDIX A

Section 4.2: PRECAUTIONS

During Use

- If a misload is detected during fluoroscopic (cine mode) inspection, do not attempt to reload the bioprosthesis. Discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components. A misload is defined as one or more of the following:
  - Inflow crown overlap (non-uniform shadow starting at the inflow) that has not ended before the 4th node from the inflow.
  - Outflow crown misalignment and/or not parallel to the paddle attachment
  - Curved or bent capsule
  - Direct load as detailed in section 9.1.4 – bullet point 17.
  - Shadow or outline in outflow indicating a bent strut

- Inflow crown overlap that has not ended before the 4th node within the capsule, increases the risk of an infold upon deployment in constrained anatomies, particularly with moderate/severe levels of calcification and/or bicuspid condition.

- Do not attempt to direct load the valve (i.e. loading the valve without completing step 17 in section 9.1.4 and simply advancing the capsule to load the valve). This increases the likelihood of excessive inflow crown overlap. If a valve has been direct loaded, discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components.

- Infold detection steps are outlined in section 9.2.4. An observation of any inward fold or crease in the valve, extending from the inflow, identified as a dark line under fluoroscopic (cine mode) inspection, may indicate an infold. If identified, and if the patient’s condition allows, do not proceed and do not release the valve.
  - Recapture, remove and discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components.
  - Pre-dilatation is strongly recommended prior to subsequent implantation attempts to minimize infold risk.
  - If initial pre-dilatation does not prevent infolding, reassess valve sizing in the presence of complex anatomies.
  - If an infold is detected and the valve is removed, consider a slightly lower depth of implantation of the second valve to provide additional space for frame expansion.

- Implanting a valve with an unresolved infold increases the risk of PVL and need for post implant dilatation, which is associated with higher rates of adverse events such as dislodgement and dissection.

- Note: Pre-dilatation may confer some risk to the patient (for example, liberation of embolic debris, damage to the tissue, or perforation of the aortic root). Patient anatomical characteristics (for example, bicuspid anatomy, excessive or asymmetric leaflet calcification, and possible leaflet fusion) should be considered by the heart team when evaluating and determining the risk/benefit of pre-dilatation and treatment plan for each patient.

Section 9.1.4 Bioprosthesis loading procedure

- Caution: Do not attempt to direct load the valve (i.e. loading the valve without completing step 17 and simply advancing the capsule to load the valve). This increases the likelihood of excessive inflow crown
If a valve has been direct loaded, discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components.

- **Note 1**: Complete fluoroscopy check under a magnified, high resolution view over an area selected to not impede the clarity of the device.
- **Note 2**: Ensure the capsule is slowly rotated 360° during the fluoroscopy check.

### Section 9.2.3 Pre-dilatation of the implant site

Adequate pre-dilatation can help reduce the need for post dilatation and may mitigate the occurrence of infolding.

Pre-dilatation may also be useful to prepare the valve for crossing by the delivery catheter system and implantation of the transcatheter valve but may also confer some additional risk to the patient (for example, liberation of embolic debris, damage to the tissue, or perforation of the aortic root). Patient anatomical characteristics (for example, bicuspid anatomy, excessive or asymmetric leaflet calcification, and possible leaflet fusion) should be considered by the heart team when evaluating and determining the risk/benefit of pre-dilatation and treatment plan for each patient.

The size and model of the pre dilatation BAV balloon should be selected such that it results in effective expansion and relief of the stenosis in the context of BAV to allow full expansion of the TAV upon implantation. Avoid balloon under sizing to ensure effective pre-dilation, therefore minimizing the risk of under expansion and infolding.

Note:
- Pre-dilatation is specifically recommended prior to implantation in the following situations:
  - Moderate / severe calcification
  - Bicuspid anatomy
  - Size 34mm valve
- Utilize an adequate size balloon for effective pre-dilatation, avoid under dilatation.

### Section 9.2.4 Deployment

1. A right / left cusp overlap projection prior to deployment with a second radiographic view without parallax, may be useful to detect infolding, particularly in the presence of complex anatomies (bicuspid nature, severe calcification). An observation of any inward fold or crease in the valve, extending from the inflow, identified as a dark line under fluoroscopy inspection, may indicate an infold. If identified and if the patient’s condition allows, do not proceed and do not release the valve.
   - Recapture, remove and discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components.
   - Pre-dilatation is strongly recommended prior to subsequent implantation attempts to minimize infold risk.
   - If initial pre-dilatation does not prevent infolding, reassess valve sizing in the presence of complex anatomies.
   - If an infold is detected and the valve is removed, consider a slightly lower depth of implantation of the second valve to provide additional space for frame expansion.

### Section 9.2.5 Bioprosthesis Recapture (optional)

1. Monitor frame during recapture to detect any presence of infolding. An observation of any inward fold or crease in the valve, extending from the inflow, identified as a dark line under fluoroscopy inspection, may indicate an infold. If identified and if the patient’s condition allows, do not proceed and do not release the valve.
• Fully complete the recapture, remove and discard the entire system. The valve, catheter, loading system, loading tray, and saline all must be replaced with new sterile components.

• Pre-dilatation is strongly recommended prior to subsequent implantation attempts to minimize infold risk.

• If initial pre-dilatation does not prevent infolding, reassess valve sizing in the presence of complex anatomies.

• If an infold is detected and the valve is removed, consider a slightly lower depth of implantation of the second valve to provide additional space for frame expansion.

Section 9.2.7 Post Implant Dilatation

If valve function or sealing is impaired due to excessive calcification, bicuspid nature, incomplete expansion or infolding, a post-implant balloon dilatation (PID) of the bioprosthesis may improve valve function and sealing.

1. Cautions:
   • Use caution when considering post dilatation in the presence of an infold to minimize dislodgement risk, particularly in the case of shallow implant depth. Consider pacing to increase valve stability, especially in patients with 34mm valves. Pace at a rate sufficient to achieve a desired decrease in systolic pressure. If pacing at a high rate, consider stepping the pacing rate down incrementally.

   • Overexpansion of the narrowest portion (waist) of the Evolut PRO+ TAV beyond the levels set forth in Table 3 has been demonstrated through bench data to cause damage to the bioprosthetic leaflets. Complaints of damage to the bioprosthetic leaflets during post-implant balloon dilatation have been reported in some clinical cases, resulting in moderate to severe aortic insufficiency, which may be detected acutely or during follow-up.

   • Snare should be available to stabilize the bioprosthesis in the event of dislodgement following post implant dilatation.

2. Consider the precautions outlined in section 4.0 Warnings and Precautions when selecting the post implant dilatation balloon model, size, and applied inflation pressure.